JP7524157B2 - 脳疾患のミトコンドリア増強療法 - Google Patents

脳疾患のミトコンドリア増強療法 Download PDF

Info

Publication number
JP7524157B2
JP7524157B2 JP2021502783A JP2021502783A JP7524157B2 JP 7524157 B2 JP7524157 B2 JP 7524157B2 JP 2021502783 A JP2021502783 A JP 2021502783A JP 2021502783 A JP2021502783 A JP 2021502783A JP 7524157 B2 JP7524157 B2 JP 7524157B2
Authority
JP
Japan
Prior art keywords
stem cells
mitochondria
mitochondrial
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532093A (ja
JP2021532093A5 (enExample
Inventor
オハナ，ナタリエ イヴギ
ハラヴィー，ウリエル
ブクスファン，シュムエル
シャー，ノア
ブラムキン，モリヤ
Original Assignee
ミノヴィア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノヴィア セラピューティクス リミテッド filed Critical ミノヴィア セラピューティクス リミテッド
Publication of JP2021532093A publication Critical patent/JP2021532093A/ja
Publication of JP2021532093A5 publication Critical patent/JP2021532093A5/ja
Application granted granted Critical
Publication of JP7524157B2 publication Critical patent/JP7524157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021502783A 2018-07-22 2019-07-22 脳疾患のミトコンドリア増強療法 Active JP7524157B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
US62/701,783 2018-07-22
US201862753936P 2018-11-01 2018-11-01
US62/753,936 2018-11-01
PCT/IL2019/050825 WO2020021538A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy of brain diseases

Publications (3)

Publication Number Publication Date
JP2021532093A JP2021532093A (ja) 2021-11-25
JP2021532093A5 JP2021532093A5 (enExample) 2022-07-29
JP7524157B2 true JP7524157B2 (ja) 2024-07-29

Family

ID=69181454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502783A Active JP7524157B2 (ja) 2018-07-22 2019-07-22 脳疾患のミトコンドリア増強療法

Country Status (4)

Country Link
US (1) US12440515B2 (enExample)
EP (1) EP3823646A4 (enExample)
JP (1) JP7524157B2 (enExample)
WO (1) WO2020021538A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7586811B2 (ja) * 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
AU2021248780A1 (en) * 2020-03-31 2022-11-10 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
CN116096861A (zh) * 2020-04-03 2023-05-09 赛立维公司 过继性细胞转移的增强

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008310A1 (en) 2007-05-02 2011-01-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2018507690A (ja) 2015-02-26 2018-03-22 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
WO2018101708A1 (ko) 2016-11-30 2018-06-07 차의과학대학교 산학협력단 미토콘드리아를 포함하는 약학 조성물

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2186636A1 (en) 1994-03-30 1995-10-12 Corinna Herrnstadt Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
EP1119368A2 (en) 1999-03-03 2001-08-01 Biogen, Inc. Methods of modulating lipid metabolism and storage
GB2350565A (en) 1999-05-28 2000-12-06 Johnson & Johnson Medical Ltd Biological wound dressings comprising mitochondria
DE19937348A1 (de) 1999-08-11 2001-02-22 Aventis Cropscience Gmbh Nukleinsäuremoleküle aus Pflanzen codierend Enzyme, die an der Stärkesynthese beteiligt sind
EP1267800A4 (en) 2000-03-31 2004-08-25 Gen Hospital Corp METHOD FOR INFLUENCING HAIR GROWTH
WO2002030418A1 (fr) 2000-10-13 2002-04-18 Chugai Seiyaku Kabushiki Kaisha Compositions servant a ameliorer le metabolisme lipidique
US20030040475A1 (en) 2001-01-16 2003-02-27 Yasuhiro Toba Agents for improving lipid metabolism and reducing high blood pressure
US7339090B2 (en) 2001-02-13 2008-03-04 Avigenics, Inc. Microinjection devices and methods of use
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
AU2002330938A1 (en) 2001-07-31 2003-02-17 Northeastern University Mitochondrial genome replenishment
EP1423504B1 (en) 2001-08-08 2009-09-23 Levesque Biosciences, Inc. Compositions and methods for isolation, propagation, and differentiation of non-embryonic human stem cells and uses thereof
US7138134B2 (en) 2001-12-18 2006-11-21 Arizona Health Consulting Group, Llc Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
CA2525560A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
EP1626732B1 (en) 2003-05-22 2013-04-03 CHIESI FARMACEUTICI S.p.A. Means for preventing and treating cellular death and their biological applications
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
US20060024277A1 (en) 2004-07-27 2006-02-02 Sivak Hannah N Method of skin care and/or treatment using extracts enriched in mitochondria
JP2006131600A (ja) 2004-11-09 2006-05-25 R & D Cell-Science Optional Medico:Kk 発毛促進のためのヒト細胞組成物
CA2609208C (en) 2005-06-10 2016-10-18 Per-Ake Albertsson Use of plant cell membrane for the treatment of obesity
AU2012201710B2 (en) 2006-05-11 2014-01-16 Regenics As Administration of cells and cellular extracts for rejuvenation
AT502353B1 (de) 2006-06-29 2007-07-15 Avl List Gmbh Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
JP5866601B2 (ja) 2008-06-18 2016-02-17 ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ 医薬組成物の製造方法
WO2011059547A2 (en) 2009-10-30 2011-05-19 Xenotech, Llc Cryopreservation of cells and subcellular fractions
US8846028B2 (en) 2010-10-28 2014-09-30 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
EA201490050A1 (ru) 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
CN102266350A (zh) 2011-07-20 2011-12-07 黄必录 逆转干细胞衰老的方案
CN102293178A (zh) 2011-08-28 2011-12-28 黄必录 使个体去衰老的方法
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
WO2013171752A1 (en) 2012-05-16 2013-11-21 Minovia Therapeutics Ltd. Compositions and methods for inducing angiogenesis
EP3459522B1 (en) 2012-12-10 2021-02-17 Regenics AS Use of egg cellular extracts for wound treatment
AU2014219026B2 (en) 2013-02-19 2018-11-29 Children's Medical Center Corporation ABCB5(+) stem cells for treating ocular disease
DE102013225588A1 (de) 2013-12-11 2014-04-17 Henkel Ag & Co. Kgaa Verwendung und Mittel zur Verbesserung der Haarstruktur
AU2015214145A1 (en) 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
EP2918458B1 (en) 2014-03-11 2016-12-07 Autoliv Development AB A vehicle braking arrangement
WO2015142855A1 (en) 2014-03-17 2015-09-24 University Of Virginia Patent Foundation Compositions and methods for treating retinopathy
CN103976935A (zh) 2014-05-28 2014-08-13 广州市白云区天芳化妆品厂 一种抗衰原液及其制备方法
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
TWI707040B (zh) 2014-09-11 2020-10-11 台灣粒線體應用技術股份有限公司 一種用於治療退化性神經疾病的細胞、含有該細胞的醫藥組合物及其應用
JP6441472B2 (ja) 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
JP6644702B2 (ja) 2014-11-14 2020-02-12 Ｊｃｒファーマ株式会社 歯髄由来多能性幹細胞を含有する筋ジストロフィー治療剤
GB201500427D0 (en) 2015-01-12 2015-02-25 Isis Innovation Method
US20180007913A1 (en) 2015-01-14 2018-01-11 Calix Ltd Improved pathogen inhibitor
MA41757A (fr) 2015-02-27 2018-01-03 Univ Connecticut Transplantation ciblée de mitochondries dans des hépatocytes
EP3302065A4 (en) 2015-05-28 2019-04-10 Celularity, Inc. PLACENTIAL STEM CELLS FOR RECOVERING THE REGENERATIVE MOTOR, CORRECTING PROTEOMIC DEFECTS AND EXTENDING THE LIFE
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
KR20190109389A (ko) 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
JP7187036B2 (ja) 2016-11-14 2022-12-12 パイアン バイオテクノロジ－ インコーポレイテッド 外因性ミトコンドリアを細胞内に送達する方法
WO2018178970A1 (en) 2017-03-26 2018-10-04 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
WO2020021535A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
EP3823643A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF LIVER DISEASES
EP3823644A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
US20210322485A1 (en) 2018-07-22 2021-10-21 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
US20200054682A1 (en) 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
CN121610569A (zh) 2019-04-30 2026-03-06 拉利玛生物医药公司 用于测定共济蛋白替代疗法的疗效的共济蛋白敏感性标志物
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
AU2021248780A1 (en) 2020-03-31 2022-11-10 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008310A1 (en) 2007-05-02 2011-01-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2018507690A (ja) 2015-02-26 2018-03-22 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
WO2018101708A1 (ko) 2016-11-30 2018-06-07 차의과학대학교 산학협력단 미토콘드리아를 포함하는 약학 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Babenko VA. et al.，Miro1 Enhances Mitochondria Transfer from Multipotent Mesenchymal Stem Cells (MMSC) to Neural Cells and Improves the Efficacy of Cell Recovery，Molecules，2018年03月19日，23巻3号，Article Number 687 (p.1-14)
Gollihue JL. et al.，Mitochondrial transplantation strategies as potential therapeutics for central nervous system trauma，Neural Regen Res，2018年02月，13巻2号，p.194-197
Torralba D. et al.，Mitochondria Know No Boundaries: Mechanisms and Functions of Intercellular Mitochondrial Transfer，Front Cell Dev Biol.，2016年，4巻，Article 00107 (p.1-11)

Also Published As

Publication number Publication date
JP2021532093A (ja) 2021-11-25
US20210275599A1 (en) 2021-09-09
WO2020021538A9 (en) 2021-02-04
EP3823646A4 (en) 2022-06-08
WO2020021538A1 (en) 2020-01-30
EP3823646A1 (en) 2021-05-26
US12440515B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
JP7524157B2 (ja) 脳疾患のミトコンドリア増強療法
JP7454548B2 (ja) 膵臓疾患のミトコンドリア増強療法
JP7458368B2 (ja) 筋疾患のミトコンドリア増強療法
US12239672B2 (en) Mitochondrial augmentation therapy of ocular diseases
JP7633148B2 (ja) 機能的ミトコンドリアで富化された幹細胞を用いたミトコンドリア増強療法
JP7522095B2 (ja) 原発性ミトコンドリア病のためのミトコンドリア増強療法
US20210252075A1 (en) Mitochondrial augmentation therapy of liver diseases
JP7586811B2 (ja) 腎臓疾患のミトコンドリア増強療法
US20210205368A1 (en) Mitochondrial augmentation therapy of renal diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240717

R150 Certificate of patent or registration of utility model

Ref document number: 7524157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150